top of page
CRISPR Therapeutics

Scientific founder, Dr. Emmanuelle Charpentier,

has gathered a team of academically world renowned scientist with the goal of curing serious genetic disease through gentic engineering treaments. Switzerland, Massachusetts and London house their three headquarters. They have raised a total of 89 million dollars for their research from various funders/ supporters. 

 [H.1]

Cellectis

Biopharmaceutical company focused on

developing immunotherapies. Techniques involve genetically engineered CAR T-cells, and research with these cells are going toward eliminating cancer. The company was founded in 1999, and as of 2015 have a partnership with MD Anderson Cancer Center, to help further research. [H.2]

Caribou Biosciences

Caribou Biosciences is a pioneer in the

revolutionary field of CRISPR. Their singular focus is on advancing applications for CRISPR-Cas9 gene editing that will help consumers and patients. Their research is on bio-based products and medical therapies, which cover the fields of: Therapeutics, Agricultural biotechnology, Biological research, and Industrial biotechnology.  [H.3]

Intellia

Intellia, who also own Extellia therapeutics

are currently conducting research on CRISPR/Cas9 applications. Using the genes CART and HSC, with the hope of creating artifical t-cells and natural killer cells to eliminate genetic and other diseases. Their unique team believes they have the correct skill set to further CRISPR technology for the benefit of the world. They are conducting research on new therapies and are under a partnership with Caribou Biosciences to complete research with joint technology. [H.4]

Editas Medicine

They were founded by world leaders in the fields

of genome editing, protein engineering, and molecular and structural biology, with expertise in CRISPR. The company's mssion is to use genome editing as a novel class human theapeutic that can be precise and corrective on the molecular level of a human genome; furthermore, to cure and prevent the causes of genetic diseases. Substantial patent filings have been submitted, and are under control of excessive amounts of intellectual property. [H.5]

Products:
Economic Impact: Industry

If we grant the selling of genetic modification as a service, we are creating a whole new work division of

individuals. In the past medications and cures have been exploited for money, because patients have no other choice but to accept the appointed costs. In a world where all your neighbors have strong and healthy children who have a daily advantage programmed into their DNA then you are subliminally forced to participate in genetic engineering within your own children. If one were to choose not to participate in this technology, they would be placing their child at a disadvantage for a life time. With this knowledge industries can harvest money from all parents at insane rates for their products which are now a necessity in society. Albeit, these are very negative effects of genetic engineering, the economic impact will also result in increased research done upon all patients. This furthers the beneficial technology at unprecedented rates.

Innovators

© 2016 by Thomas Abbott and Chubi Yambao. Proudly created with Wix.com

  • Facebook App Icon
  • Twitter App Icon
  • Google+ App Icon
bottom of page